Effects of briakinumab treatment for moderate to severe psoriasis on health‐related quality of life and work productivity and activity impairment: results from a randomized phase III study
Authors:
- 17 May 2013
- journal article
- research article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 28 (6) , 790-798
Abstract
Background: Psoriasis is known to have a significant negative impact on a patient's health‐related quality of life, including social, recreational and work activities.Objective: To evaluate the effects of briakinumab on quality of life and work productivity measures in patients with moderate to severe psoriasis.Methods: Patients received either briakinumab (n = 981) or placebo (n = 484) during the 12‐week induction phase of trial M06‐890. At week 12, patients with a Physician's Global Assessment score of ‘Clear’ or ‘Minimal’ entered the 40‐week maintenance phase and were to receive briakinumab every 4 weeks, briakinumab every 12 weeks, or placebo. At weeks 12 and 52, treatment groups were compared using mean change from baseline in health‐related quality of life and Work Productivity and Activity Impairment Questionnaire scores and the percentage of patients with minimum clinically important differences.Results: At week 12, more than half of the briakinumab‐treated patients achieved improvements meeting or exceeding minimum clinically important differences for Dermatology Life Quality Index (75.9%), and psoriasis‐ (64.8%), and psoriatic arthritis‐related (54.1%) pain scores; 48.4% achieved improvements for activity impairment. Although improvements in quality of life and work productivity measures were maintained at week 52 for both briakinumab regimens, responder rates were consistently greater in the every‐4‐week group than in the every‐12‐week group.Conclusion: Briakinumab treatment resulted in clinically significant improvements in quality of life and work productivity in adults with moderate to severe psoriasis. Maintenance therapy was associated with a more pronounced benefit for the every‐4‐week briakinumab regimen.Keywords
Funding Information
- AbbVie Inc.
- Arbor Communications, Inc.
This publication has 41 references indexed in Scilit:
- Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trialBritish Journal of Dermatology, 2009
- Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL studyJournal of the European Academy of Dermatology and Venereology, 2009
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)The Lancet, 2008
- Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasisBritish Journal of Dermatology, 2007
- Development, cytokine profile and function of human interleukin 17–producing helper T cellsNature Immunology, 2007
- Impact of adalimumab treatment on patient‐reported outcomes: Results from a Phase III clinical trial in patients with moderate to severe plaque psoriasisJournal of Dermatological Treatment, 2007
- Impact of Stroke on Health-Related Quality of Life in the Noninstitutionalized Population in the United StatesStroke, 2006
- Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trialBritish Journal of Dermatology, 2005
- Intramuscular Alefacept Improves Health-Related Quality of Life in Patients with Chronic Plaque PsoriasisDermatology, 2003
- The Validity and Reproducibility of a Work Productivity and Activity Impairment InstrumentPharmacoEconomics, 1993